AbbVie (ABBV) Research & Development (2012 - 2026)

AbbVie (ABBV) has reported Research & Development for 15 consecutive years, with $2.3 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Research & Development rose 10.0% year-over-year to $2.3 billion in Q2 2026; TTM through Jun 2026 was $9.7 billion, a 25.86% decrease from a year earlier, with the FY2025 full-year figure at $9.1 billion, down 28.89% from the prior year.
• Research & Development was $2.3 billion for Q2 2026 at AbbVie, down from $2.5 billion in the prior quarter.
• Over five years, Research & Development peaked at $6.8 billion in Q4 2024 and troughed at $1.5 billion in Q1 2022.
• A 5-year average of $2.3 billion and a median of $2.0 billion in 2024 frame the typical range for Research & Development.
• Across the five-year window, Research & Development surged 251.53% in 2024 and slumped 61.93% in 2025, its largest moves.
• Over 5 years, Research & Development stood at $1.8 billion in 2022, then gained by 7.65% to $1.9 billion in 2023, then surged by 251.53% to $6.8 billion in 2024, then tumbled by 61.93% to $2.6 billion in 2025, then retreated by 9.11% to $2.3 billion in 2026.
• The last three Research & Development figures came in at $2.3 billion (Q2 2026), $2.5 billion (Q1 2026), and $2.6 billion (Q4 2025), per Business Quant data.